Skip to main content
Apontis Pharma AG logo

Apontis Pharma AG — Investor Relations & Filings

Ticker · APPH ISIN · DE000A3CMGM5 LEI · 894500ETO1J6MR8PDF91 F Manufacturing
Open in API
Filings indexed 114 across all filing types
Latest filing 2021-06-10 Regulatory Filings
Country DE Germany
Listing F APPH

About Apontis Pharma AG

https://apontis-pharma.de/en/

Apontis Pharma AG is a pharmaceutical company that specializes in the development, marketing, and distribution of 'Single Pills'. These are fixed-dose combination drugs that unite two or three active pharmaceutical ingredients into a single tablet. The company's portfolio primarily focuses on treating cardiovascular diseases and other chronic conditions. By simplifying treatment regimens, the Single Pill approach aims to improve patient adherence and therapy outcomes, offering medical and economic benefits to the healthcare system. Apontis Pharma also engages in co-marketing activities for established pharmaceutical products.

Recent filings

Filing Released Lang Actions
APONTIS PHARMA AG: Post-Stabilisation disclosure - Partial exercise of the Greenshoe Option
Regulatory Filings Classification · 1% confidence The document is a formal disclosure titled "APONTIS PHARMA AG: Post-Stabilisation disclosure – Partial exercise of the Greenshoe Option." It explicitly references regulatory articles concerning stabilization measures (Commission Delegated Regulation (EU) 2016/1052) and market abuse (Regulation (EU) 596/2014). This type of announcement details the conclusion of stabilization activities following an offering, including the number of shares bought back during stabilization and the partial exercise of the over-allotment option (Greenshoe). This activity is directly related to the issuance and trading of securities, but it is not the primary offering document (like a prospectus), nor is it a standard periodic financial report (10-K, IR). It is a specific regulatory disclosure related to capital market activities. Since it details the outcome of stabilization and Greenshoe exercise, it falls under the umbrella of capital/financing updates or a specific regulatory filing. Given the highly specific nature of the content (stabilization, Greenshoe option exercise, offer price, trading venue details), it is best classified as a Capital/Financing Update (CAP) as it directly relates to the mechanics of the recent share offering and its aftermath, or RNS as a general regulatory disclosure. However, since the definitions do not explicitly cover 'Stabilization Disclosure,' and it is a mandatory disclosure following a capital event, 'CAP' is a strong fit, but 'RNS' (Regulatory Filings - fallback) is safer if CAP is interpreted narrowly as only primary fundraising announcements. Given the context of DGAP news dissemination and the specific regulatory nature, RNS is the most appropriate general regulatory category for this specific post-offering disclosure that doesn't fit the other financial reporting codes.
2021-06-10 English
APONTIS PHARMA AG: Notification on the implementation of stabilization measures
Capital/Financing Update Classification · 1% confidence The document is titled "APONTIS PHARMA AG: Notification on the implementation of stabilization measures" and explicitly references disclosure requirements under the Market Abuse Regulation (EU) No 596/2014 regarding "stabilisation measures." It details the stabilization manager, the securities involved (ordinary shares), the offer price, and a transaction log of purchases (P) made during the stabilization period. This content directly relates to actions taken to support the price of newly issued securities, which falls under financing or capital market activities. Since it is a notification about stabilization activities following an offer, it best fits the 'Capital/Financing Update' category (CAP) rather than a general regulatory filing (RNS) or a transaction in own shares (POS), as stabilization is a specific post-IPO/offering mechanism.
2021-06-10 English
APONTIS PHARMA AG: Notification on the implementation of stabilization measures
Share Issue/Capital Change Classification · 1% confidence The document is titled "APONTIS PHARMA AG: Notification on the implementation of stabilization measures" and explicitly references disclosure requirements under the Market Abuse Regulation (EU) No 596/2014 regarding the implementation of stabilisation measures following an offer. It details the stabilization manager, the securities involved (ordinary shares), the offer price, and a table showing specific purchase transactions ('P') executed on the Frankfurt Stock Exchange (XETR) as part of this stabilization effort. This content relates directly to market activities following an offering, specifically share stabilization, which falls under capital market transactions. While it is a regulatory disclosure, it is not a standard periodic report (10-K, IR) or a general announcement (RNS). It is a specific notification about capital market activity, most closely aligning with 'Capital/Financing Update' (CAP) or potentially a specific type of regulatory filing. Given the detailed nature of the stabilization transactions and the reference to the offering, 'CAP' is the most appropriate fit as it covers financing activities, which includes post-IPO stabilization measures. It is not a general regulatory filing (RNS) because it is highly specific to a capital market event.
2021-05-28 English
APONTIS PHARMA AG Trading Update: Strong revenues and earnings growth with Single Pills continues in the first four months of 2021
Earnings Release Classification · 1% confidence The document is titled 'APONTIS PHARMA AG Trading Update: Strong revenues and earnings growth with Single Pills continues in the first four months of 2021' and explicitly uses the keyword 'Quarterly / Interim Statement' in the DGAP header. It provides key financial highlights (revenues, EBITDA, EBITDA margin) for the period January to April 2021. This content structure—a brief announcement summarizing performance for a period shorter than a full year—is characteristic of an Interim Report (IR). It is not a full Annual Report (10-K) or a simple Earnings Release (ER) which usually only contains the absolute minimum figures; this provides more context and management commentary typical of an IR. Q1 2021
2021-05-20 English
APONTIS PHARMA AG: Notification on the implementation of stabilization measures
Capital/Financing Update Classification · 1% confidence The document is titled "APONTIS PHARMA AG: Notification on the implementation of stabilization measures" and explicitly references the Market Abuse Regulation (EU) No 596/2014 and Delegated Regulation (EU) 2016/1052 concerning stabilization measures. It details transactions (purchases) conducted by a stabilization manager related to an offer of ordinary shares. This type of regulatory disclosure regarding market stabilization activities following an offering is a specific type of corporate action related to capital markets, but it doesn't fit neatly into the primary categories like 10-K, ER, or IR. It is a specific regulatory disclosure concerning the offering/capital structure. Since it details the stabilization activities post-offering, it is most closely related to financing/capital structure changes, but the specific nature of reporting stabilization transactions points towards a specialized regulatory announcement. Given the options, it is a specific regulatory disclosure that doesn't fit the core financial reports (10-K, IR, ER) or insider trading (DIRS). It is a notification about actions taken during or immediately following a capital raise/offering, which aligns best with Capital/Financing Update (CAP) or, if viewed purely as a mandatory disclosure not covered elsewhere, Regulatory Filings (RNS). However, stabilization reports are often considered part of the capital raising process. Since the document is a formal notification detailing the stabilization manager's actions post-offering, it is a specific regulatory disclosure related to capital market activity. Given the detailed nature of the stabilization report, it is a specific regulatory filing. If we must choose the most specific category related to capital structure events, CAP is plausible, but stabilization reports are often classified under general regulatory disclosures when a specific 'Stabilization Report' code isn't available. Comparing the definitions, it is a mandatory disclosure related to the securities offering process. Since it is a formal notification about market activity related to securities, and not a general report announcement (RPA), it fits best under the general Regulatory Filings (RNS) as a specific, non-standard report, or potentially CAP. Given the context of DGAP news dissemination and the specific regulatory citation (MAR), RNS is the safest fallback for specific regulatory disclosures not covered by other codes. However, stabilization is intrinsically linked to the offering/capital structure. Let's re-evaluate: It is a notification about stabilization measures related to an offer. This is a specific disclosure required under MAR related to the offering process. It is not a general announcement of a report (RPA). It is not DIRS (insider trading). It is not SHA (share issue/change). It is a specific regulatory disclosure. I will classify it as RNS as the most appropriate general regulatory filing category for this specific MAR disclosure.
2021-05-19 English
APONTIS PHARMA AG sets placement price for its IPO at EUR 19.00 per share
Capital/Financing Update Classification · 1% confidence The document is a press release announcing that APONTIS PHARMA AG has set the placement price for its Initial Public Offering (IPO) at EUR 19.00 per share. It details the total placement volume, market capitalization, expected free float, and the intended use of proceeds. This type of announcement, detailing fundraising, capital structure changes, and the pricing of new shares before they begin trading, directly corresponds to the definition of a Capital/Financing Update. It is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). While it relates to a corporate event, it is specifically about the financing/capital raising aspect of the IPO, making 'CAP' the most precise fit over the general 'RNS' fallback.
2021-05-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.